Regeneron Pharmaceuticals, Inc.
REGN
$718.16
-$26.67-3.58%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 11.61% | 16.62% | 0.53% | -7.77% | -8.87% |
| Total Depreciation and Amortization | 14.70% | 15.05% | 14.65% | 18.82% | 23.32% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -54.29% | -159.55% | -89.83% | -38.97% | -45.80% |
| Change in Net Operating Assets | -557.07% | -269.85% | -474.60% | 112.78% | 61.32% |
| Cash from Operations | -3.78% | -18.70% | -14.10% | 10.70% | -8.39% |
| Capital Expenditure | -5.19% | -30.40% | -26.61% | -7.63% | -21.78% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 69.95% | 82.78% | -- | 76.16% | 76.16% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 28.85% | 51.50% | 45.30% | -167.95% | 18.64% |
| Cash from Investing | 22.51% | 42.03% | 34.54% | -100.28% | 15.84% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 27.92% | 37.66% | 33.33% | -9.49% | -24.61% |
| Repurchase of Common Stock | -23.74% | -12.26% | 6.38% | 4.04% | -16.10% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -22.93% | 5.06% | 32.73% | -1.74% | -77.41% |
| Foreign Exchange rate Adjustments | -75.00% | 133.33% | -100.00% | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 34.80% | 88.96% | 98.53% | -331.57% | -272.44% |
